Sirak Pharmaceuticals Private Limited - Company Profile

It is a pharma private limited company based in Hyderabad, Telangana, India, established in 2008.
2008 Hyderabad, Telangana, India Active
Last Updated:
Access Report
About Sirak Pharmaceuticals Private Limited

Sirak Pharmaceuticals Private Limited, a active private limited company, was established on 08 January 2008 in Hyderabad, Telangana, India. Engaging in pharma contract r&d within the professional, scientific and technical sector, it holds CIN: U24232TG2008PTC057045. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹1.50 Cr and a paid-up capital of ₹1.34 Cr.

It upholds a compliant status. Its leadership includes Swaroopkumar Venkata Satya Vakkalanka (Director), Sita Samyukta Vakkalanka (Director), Satya Kameswari Vakkalanka (Director). Past directors included Sita Samyukta Vakkalanka, Thappali Ramaswamy Sethuraman Satheesh Manikandan. It holds ₹11.48 Cr open charges and ₹4.95 Cr settled loans. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at Office No. 01B1 12A01B1, 12A (13Th) Floor, Manjeera Trinity Corporation, Jntu Rd, K, Ukatpally, Hyderabad, Telangana, 500072.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U24232TG2008PTC057045

  • Registration Number

    057045

  • Incorporation Date

    08 January 2008

  • Authorized Capital

    ₹1.50 Cr

  • Paid-Up Capital

    ₹1.34 Cr

  • ROC Code

    Roc Hyderabad

  • Listing Status

    Unlisted

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 1.50 Cr
  • Paid Up Capital ₹ 1.34 Cr
  • Company Age 18 Year, 4 Months
  • Last Filing with ROC 31 Mar 2025
  • Open Charges ₹ 11.48 Cr
  • Satisfied Charges ₹ 4.95 Cr
  • Revenue Growth **** 80.33%
  • Profit Growth **** 189.85%
  • Ebitda **** 201.04%
  • Net Worth 99.67%
  • Total Assets **** 28.85%
Company report

Sirak Pharmaceuticals Private Limited

Company Report FY 2026-2027

Comprehensive Company Insights

Explore comprehensive insights into Sirak Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Sirak Pharmaceuticals Private Limited?
Current Directors
Name Designation Appointment Date Status
Swaroopkumar Venkata Satya Vakkalanka Director 08 Jan 2008 Current
Sita Samyukta Vakkalanka Director 01 Apr 2025 Current
Satya Kameswari Vakkalanka Director 08 Jan 2008 Current
Thappali Ramaswamy Sethuraman Satheesh Manikandan Director 31 Mar 2022 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Additional Director 29 Sep 2025 Past
Pramod Abcsdd Additional Director 30 Sep 2022 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Sirak Pharmaceuticals.

Sirak Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 80.33% increase. The company also saw a substantial improvement in profitability, with a 189.85% increase in profit. The company's net worth Soared by an impressive increase of 99.67%.

Sirak Pharmaceuticals revenue growth over time
Sirak Pharmaceuticals profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 80.33%
*******
*******
*******
*******
Revenue from Operations
*******
 -4.12%
*******
*******
*******
*******
Total Assets
*******
 28.85%
*******
*******
*******
*******
Profit or Loss
*******
 189.85%
*******
*******
*******
*******
Net Worth
*******
 99.67%
*******
*******
*******
*******
EBITDA
*******
 201.04%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Sirak Pharmaceuticals?

Unlock access to Sirak Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹114,800,000.00

Satisfied Charges

₹49,500,000.00

Charges Breakdown by Lending Institutions
  • Yes Bank Limited : 7.45 Cr
  • Hdfc Bank Limited : 4.03 Cr
Latest Charge Details
Date Lender Amount Status
06 Feb 2024 Hdfc Bank Limited ₹4.03 Cr Open
29 Oct 2022 Yes Bank Limited ₹7.45 Cr Open
29 Feb 2020 Yes Bank Limited ₹1.00 Cr Satisfied
01 Nov 2016 Hdfc Bank Limited ₹2.45 Cr Satisfied
17 Apr 2015 Hdfc Bank Limited ₹1.50 Cr Satisfied

Explore comprehensive loan charge details -

How Many Employees Work at Sirak Pharmaceuticals?

Unlock and access historical data on people associated with Sirak Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Sirak Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sirak Pharmaceuticals's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Sirak Pharmaceuticals
Recent Activity within the Organization
  • Annual General Meeting

    Progress on Sirak Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was documented.

  • Director Appointment

    Sita Samyukta Vakkalanka was appointed as a Director was appointed as a Director on 01 Apr 2025 & has been associated with this company since 1 year 1 month . was recorded as a recent event.

  • Balance Sheet

    Progress on Sirak Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad. was documented.

  • Charges

    Progress on A charge with Hdfc Bank Limited amounted to Rs. 4.03 Cr with Charge ID 100865612 was registered on 06 Feb 2024. was documented.

  • Charges

    Progress on A charge with Yes Bank Limited amounted to Rs. 7.45 Cr with Charge ID 100628562 was registered on 29 Oct 2022. was documented.

  • Charges

    A charge registered on 01 Nov 2016 via Charge ID 100098221 with Hdfc Bank Limited was fully satisfied on 23 May 2022. was recorded as a recent event.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Sirak Pharmaceuticals Private Limited?

The CIN of Sirak Pharmaceuticals Private Limited is U24232TG2008PTC057045.

Where is Sirak Pharmaceuticals Private Limited headquartered?

Sirak Pharmaceuticals Private Limited is headquartered at Office No. 01B1 12A01B1, 12A (13Th) Floor, Manjeera Trinity Corporation, Jntu Rd, K, Ukatpally, Hyderabad, Telangana, 500072.

When was Sirak Pharmaceuticals Private Limited incorporated?

Sirak Pharmaceuticals Private Limited was incorporated on 08 January 2008.

Who are the current directors of Sirak Pharmaceuticals Private Limited?

The current directors of Sirak Pharmaceuticals Private Limited are

What is the primary industry of Sirak Pharmaceuticals Private Limited?

The primary industry of Sirak Pharmaceuticals Private Limited is Professional, Scientific And Technical.

Is Sirak Pharmaceuticals Private Limited a listed company?

Sirak Pharmaceuticals Private Limited is unlisted.

What is the capital structure of Sirak Pharmaceuticals Private Limited?

The authorized capital of Sirak Pharmaceuticals Private Limited is ₹1.50 Cr, and the paid-up capital is ₹1.34 Cr.

What is the compliance status of Sirak Pharmaceuticals Private Limited?

The compliance status of Sirak Pharmaceuticals Private Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available